## Haematologica HAEMATOL/2020/272559 Version 3

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia

Vincent Jachiet, Guillaume Moulis, Jérome Hadjadj, Julie Seguier, Kamel Laribi, Nicolas Schleinitz, Norbert Vey, Karim Sacre, Bertrand Godeau, Odile Beyne Rauzy, Romain Bouvet, Jonathan Broner, Natacha Brun, Thibault Comont, Clément Gaudin, Olivier Lambotte, Lenaïg Le Clech, Pierre Peterlin, Frédérique Roy-Peaud, Clémentine Salvado, Mathilde Versini, Françoise Isnard, Jean Emmanuel Kahn, Delphine Gobert, Lionel Adès, Pierre Fenaux, Olivier Fain, and Arsène Mekinian

Collaborative Groups: MINHEMON (French Network of dysimmune disorders associated with hemopathies), GFM (Groupe Francophone des Myélodysplasies), CERECAI (Centre de Référence des Cytopénies Auto-Immunes de l'adulte), CARMEN (Cytope nies Auto-immunes: Registre Midi-Pyre ne EN)

Disclosures: GM received research grants form CSL Behring and Novartis for the CARMEN registry in 2016 and 2017-2018. These sponsors have no role in data collection and have not the property of data; they have no role in the conception, the methodology, the analyses, the interpretation of the studies conducted in the registry; the manuscript has not been submitted to sponsors before publication. GM also received research grants from Novartis, Grifols, the Institut Servier and meeting attendance grants from Amgen and Novartis.

Contributions: VJ, GM, PF, OF and AM designed the research, analyzed data, wrote the paper and participated to relecture and approval of the manuscript. JH, JS, KL, NS, NV, KS, BG, ODR, RB, JB, NB, TC, CG, OL, LLC, PT, FRP, CS, MV, FI, MV, DG, JEK, participated to the patient's data, analyse, relecture and approval of the manuscript.